Results 1 to 10 of about 475,892 (311)
Pharmacokinetics, Pharmacodynamics, and Safety of ET-26 in Subjects with Mild to Moderate Renal Impairment [PDF]
Drugs in R&DBackground and Objectives ET-26 is a novel etomidate analog with reduced adrenal suppression. This study evaluated its pharmacokinetics (PK), pharmacodynamics (PD), and safety in subjects with mild to moderate renal impairment.
Fan Yang +10 more
doaj +2 more sources
Modeling and predicting drug pharmacokinetics in patients with renal impairment
Expert Review of Clinical Pharmacology, 2011 Current guidance issued by the US FDA to assess the impact of renal impairment on the pharmacokinetics of a drug under development has recently been updated to include evaluation of drugs with nonrenal elimination routes.
Karen Rowland Yeo +2 more
exaly +2 more sources
Serum β2-microglobulin, cystatin-C, and urinary KIM-1 as predictors of early renal impairment in women with diabetes in pregnancy: a prospective cohort study [PDF]
BMC Endocrine DisordersBackground Diabetes in pregnancy (DIP), including pregestational diabetes mellitus (PGDM) and gestational diabetes mellitus (GDM), increases the risk of early renal impairment. However, conventional renal markers are often insensitive in the early stages.
Xue Zhao +3 more
doaj +2 more sources
Renal Impairment and Prognosis of Patients with Atrial Fibrillation Undergoing Coronary Intervention - The AFCAS Trial. [PDF]
PLoS ONE, 2015 Renal impairment is a well-known risk factor for cardiovascular complications, but the effect of different stages of renal impairment on thrombotic/thromboembolic and bleeding complications in patients with atrial fibrillation (AF) undergoing ...
Heli M Lahtela +8 more
doaj +1 more source
MicroRNA Expression Profiling in Age-Dependent Renal Impairment
Frontiers in Medicine, 2022 BackgroundAge-dependent renal impairment contributes to renal dysfunction in both the general population and young and middle-aged patients with renal diseases.
Katsunori Yanai +7 more
doaj +1 more source
PLoS ONE, 2021 ObjectiveRitonavir-boosted protease inhibitors (bPI) in people living with HIV (PLWH) have been associated with renal impairment. Limited data are available from rural sub-Saharan Africa.MethodsUsing data from the Kilombero and Ulanga Antiretroviral ...
Herry Mapesi +12 more
doaj +1 more source
Vildagliptin in renal impairment [PDF]
Journal of Nephrology, 2014 We read with interest the article by Schernthaner and Schernthaner [1] entitled ‘‘Diabetic nephropathy: new approaches for improving glycemic control and reducing risk’’, published in the November/December 2013 edition of J Nephrol. While we commend the authors for highlighting this important topic, we are writing to draw attention to what we believe ...
Neelesh, Dongre, Wolfgang, Kothny
openaire +2 more sources
Wave of renal impairment [PDF]
BMJ Case Reports, 2018 We present a case of a 51-year-old man who went to the emergency department after an almost-drowning episode, presenting with muscular weakness, myalgia and dark urine. Laboratory data showed a severe rhabdomyolysis (creatine kinase 497 510 U/L). Despite aggressive fluid therapy, an oliguric acute kidney injury was established with temporary need of ...
Helena, Pinto +3 more
openaire +2 more sources
BMC Primary Care, 2023 Purpose This study aimed to examine the association between renal impairment and polypharmacy among older Palestinian patients visiting primary healthcare centers and to examine potentially inappropriate medications among older patients.
Shayma Naghnaghia +5 more
doaj +1 more source
Pharmacokinetics of bempedoic acid in patients with renal impairment
Clinical and Translational Science, 2022 Bempedoic acid is an ATP citrate lyase inhibitor approved for the treatment of hypercholesterolemia. The objective of this phase I study was to assess the pharmacokinetics (PKs) and safety of bempedoic acid in 24 subjects with normal renal function or ...
Benny M. Amore +4 more
doaj +1 more source